Combination of specific allergen and probiotics induces specific regulatory B cells and enhances specific immunotherapy effect on allergic rhinitis.
Combination of specific allergen and probiotics induces specific regulatory B cells and enhances specific immunotherapy effect on allergic rhinitis.
复制标题
特异性过敏原与益生菌联合诱导特异性调节性B细胞，增强对过敏性鼻炎的特异性免疫治疗效果。
DOI：
10.18632/oncotarget.10946
复制
发表时间：
2016-08-23
期刊：
影响因子：
--
通讯作者：
Yang PC
中科院分区：
文献类型：
--
作者：
Xu LZ;Yang LT;Qiu SQ;Yang G;Luo XQ;Miao BP;Geng XR;Liu ZQ;Liu J;Wen Z;Wang S;Zhang HP;Li J;Liu ZG;Li HB;Yang PC
过敏原特异性免疫治疗（SIT）对变态反应性疾病的疗效有待提高。益生菌可以调节免疫反应。本研究旨在通过与酪酸梭菌（Cb）联合给药来促进SIT治疗变应性鼻炎（AR）的效果。在本研究中，对螨过敏原致敏的AR患者入组本研究，并接受SIT或/和Cb治疗。观察鼻症状总积分（NSS）、药物治疗积分、血清特异性IgE水平及辅助性T细胞（Th）2细胞因子水平。通过免疫学方法评估AR患者免疫调节的改善。结果显示，单用SIT治疗AR患者可显著降低NSS和药物评分，但不改变血清特异性IgE、Th 2细胞因子和皮肤点刺试验（SPT）指数。SIT组停药1个月后AR临床症状复发。CB联合给药显著增强SIT对AR的疗效，如NSS抑制、药物评分、血清特异性IgE、Th 2细胞因子和SPT指数所示;调节性B细胞频率也显著增加。在整个观察期内，甚至在停止给药后，对AR的这种作用仍得以维持。丁酸可阻断抗原特异性B细胞中组蛋白去乙酰化酶-1的激活、β链启动子的下游活性和IgE的产生。丁酸诱导B细胞表达IL-10的前提是特异性抗原激活B细胞受体。结论：Cb可明显增强SIT对AR的疗效。
The therapeutic efficacy of allergen specific immunotherapy (SIT) on allergic diseases is to be improved. Probiotics can regulate immune response. This study aims to promote the effect of SIT on allergic rhinitis (AR) by co-administration with Clostridium butyricum (Cb). In this study, patients with AR sensitized to mite allergens were enrolled to this study, and treated with SIT or/and Cb. The therapeutic efficacy was evaluated by the total nasal symptom scores (NSS), medication scores, serum specific IgE levels and T helper (Th)2 cytokine levels. The improvement of immune regulation in the AR patients was assessed by immunologic approaches. The results showed that treating AR patients with SIT alone markedly reduced NSS and medication scores; but did not alter the serum specific IgE, Th2 cytokines and skin prick test (SPT) index. The clinical symptoms on AR in SIT group relapsed one month after stopping SIT. Co-administration of Cb significantly enhanced the efficacy of SIT on AR as shown by suppression of NSS, medication scores, serum specific IgE, Th2 cytokines and SPT index; the regulatory B cell frequency was also markedly increased. Such an effect on AR was maintained throughout the observation period even after stopping the treatment. Butyrate blocked the activation of histone deacetylase-1, the downstream activities of epsilon chain promoter activation, and the IgE production in the antigen specific B cells. On the other hand, butyrate induced the IL-10 expression in B cells with a premise of the B cell receptor activation by specific antigens. In conclusion, administration with Cb can markedly enhance the efficacy of SIT on AR.